Pharma Law and Business – A Monthly Roundup December 2012
Litigation always factors into the pharmaceutical world, but the US Supreme Court commanded a special place in recent days. The high court figured in no fewer than four contentious issues that, not...
View ArticlePharma Law and Business – A Monthly Roundup for January 2013
Not surprisingly, 2013 began with a predictable rush of interesting news. So here are some of the most recent highlights, from court rulings and medical study findings to FDA doings and steps taken to...
View ArticlePharma Law and Business: A Month Roundup for February 2013
The FDA decided not to pursue a re-hearing before a federal appeals court that recently ruled the federal government could not prosecute a sales rep who promoted off-label uses of a medicine because...
View ArticlePharma Law and Business Roundup for March 2013
In response to the scandal over a fungal meningitis outbreak, the FDA has begun a crackdown on compounding pharmacies and targeting about 30 ‘high risk’ operations in nearly a dozen states. San...
View ArticleBio-Pharma at the U.S. Supreme Court
Since my last article here on IPWatchdog.com, the pharmaceutical industry has been simply overflowing with interesting developments, including the US Supreme Court hearing arguments concerning three...
View ArticlePharma Law and Business Roundup: June 2013
After years of debate and controversy, the US Supreme Court ruled that drugmakers can face lawsuits over so-called pay-to-delay patent settlements, but that such deals should not necessarily be assumed...
View ArticlePharma Scandals: Bribery, Insider Trading and Paula Deen
The summer may be in full swing, but the torrent pace of news and interesting developments has not subsided at all. Hot days simply yield hot stories. Unarguably, the most sensational item over the...
View ArticlePharma Update July 2013: FDA, Preemption & SCOTUS
The FDA is following through on plans to issue a proposed rule to revise regulations to allow generic drugmakers to update labeling. The rule would update current regulations that prevent generic...
View Article
